Investigational peptide
AOD-9604
An investigational modified growth-hormone fragment that reached obesity trials but did not become an approved weight-loss medicine.
- Sequence
- YLRIVQCRSVEGSCGF
Evidence confidence
Human
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Animal
4/5
Substantial animal evidence
4 citations
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
Not yet assessed
Trust Engine review pending.
Claimed uses
- Limited human
- Low to limited
- Insufficient
- Insufficient
Mechanisms
- Lipolysis stimulation (proposed)
- Lipolysis and fat oxidation
- C-terminal growth hormone fragment lipid signalling
Safety notes
Modern long-term safety data are limited. Product quality, injection complications, metabolic effects and use alongside other weight-loss agents require caution.
Regulation
- Not generally licensed as an obesity or weight-loss medicine. Product and sporting status should be checked by jurisdiction.
- Not approved as a prescription obesity medicine. Regulatory treatment of compounded or research-labelled supply varies, and it is prohibited in sport.
References
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model · 2015
- AOD-9604 Metabolic · 2004
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment · 2001
- The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism following chronic treatment in obese mice and beta-3 adrenergic knockout mice · 2001
- Metabolic studies of a synthetic lipolytic domain of human growth hormone · 2000
Last reviewed
11 July 2026